Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

In both trials, lenacapavir was safe and generally well-tolerated. Two smaller Phase 2 studies are now evaluating lenacapavir and Truvada PrEP for cisgender women (PURPOSE 3) and people who inject ...

Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' ...

Descovy has been shown to be effective as PrEP in helping prevent HIV in a clinical study. People in the study took either Descovy or Truvada, which is another medication used for PrEP.

Shares of Gilead Sciences, Inc. GILD were down 2.47% after the Wall Street Journal reported that The Health and Human ...

Gilead Sciences has said it plans to challenge patents held by the US government on the use of its HIV drug Truvada for pre-exposure prophylaxis (PrEP). In a move that will incense critics who ...

Like most prescribed medications, all three brands PrEP brands feature side effects. Here's how to prepare for them.

HIV pre-exposure prophylaxis (PrEP) with daily oral tenofovir disoproxil fumarate (TDF) or TDF–emtricitabine (FTC) has been shown to be effective against sexual and injection-drug related HIV ...

Medicare has covered FDA-approved Pre-exposure Prophylaxis (PrEP) oral or injectable antiretroviral drugs such as Truvada, as well as counseling sessions for HIV risk assessment, medication ...

there are two FDA-approved daily oral medications for pre-exposure prophylaxis (PrEP) — Truvada and Descovy. Descovy (FTC 200 mg/TAF 25 mg) for PrEP has witnessed good uptake. It maintains more ...